Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique

被引：0
|
作者：
Bonny Parkinson
Sallie-Anne Pearson
Rosalie Viney
机构：
[1] University of Technology,Centre for Health Economics Research and Evaluation (CHERE)
[2] Sydney,Pharmacoepidemiology and Pharmaceutical Policy Research Group, Faculty of Pharmacy
[3] The University of Sydney,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Economics; Cost-utility analysis; Cost-effectiveness analysis; Breast neoplasms; Metastatic; Trastuzumab; I18; D61;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：93 / 112
页数：19
相关论文
共 50 条
  • [41] A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
    Khoirunnisa, Sudewi Mukaromah
    Suryanegara, Fithria Dyah Ayu
    de Jong, Lisa Aniek
    Setiawan, Didik
    Postma, Maarten Jacobus
    PHARMACOECONOMICS-OPEN, 2024, 8 (04) : 511 - 524
  • [42] Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
    Zagouri, Flora
    Sergentanis, Theodoros N.
    Bartsch, Rupert
    Berghoff, Anna S.
    Chrysikos, Dimosthenis
    de Azambuja, Evandro
    Dimopoulos, Meletios-Athanassios
    Preusser, Matthias
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (01) : 13 - 22
  • [43] Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
    Flora Zagouri
    Theodoros N. Sergentanis
    Rupert Bartsch
    Anna S. Berghoff
    Dimosthenis Chrysikos
    Evandro de Azambuja
    Meletios-Athanassios Dimopoulos
    Matthias Preusser
    Breast Cancer Research and Treatment, 2013, 139 : 13 - 22
  • [44] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [45] Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review
    Kyriazoglou, Anastasios
    Kaparelou, Maria
    Goumas, Georgios
    Liontos, Michael
    Zakopoulou, Roubini
    Zografos, Eleni
    Zygogianni, Anna
    Dimopoulos, Meletios Athanasios
    Zagouri, Flora
    BREAST CARE, 2022, 17 (01) : 63 - 70
  • [46] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
  • [47] Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
    Gradishar, W. J.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2492 - 2500
  • [48] Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
    Park, I. H.
    Ro, J.
    Lee, K. S.
    Nam, B. H.
    Kwon, Y.
    Shin, K. H.
    ANNALS OF ONCOLOGY, 2009, 20 (01) : 56 - 62
  • [49] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
    Haq, R.
    Gulasingam, P.
    CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
  • [50] Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1425): : 75 - 76
12345